
Ozempic Gastroparesis Lawsuit
Patients who used Ozempic, Mounjaro, or Saxenda and suffered severe gastrointestinal injuries including gastroparesis, bowel obstruction, or ileus may be eligible to file a claim. Get your free case review today.
Get A Free Case ReviewATTENTION: OZEMPIC USERS
If you developed gastroparesis, bowel obstruction, or severe stomach problems after using Ozempic, you may be eligible to file a claim!
Consumers Injury Help offers a free, confidential case review and can connect you with an independent attorney. Over 3,000 cases are consolidated in MDL 3094 before the Eastern District of Pennsylvania. Bellwether trials are expected in late 2026.
Find Out if You Qualify
Free, Confidential Case Review
FREE CASE REVIEW
SEE IF YOU MAY QUALIFY
How do we help YOU?
MDL 3094 consolidates over 3,191 Ozempic lawsuits in the Eastern District of Pennsylvania. Lawsuits allege Novo Nordisk failed to warn that semaglutide carries a 3.3× higher gastroparesis risk. The FDA updated warnings in 2023 and 2025 — but thousands were already harmed. Bellwether trials are expected late 2026.
How does filing a claim work?
- 1. Tell us what happened. Choose the product and answer a few questions.
- 2. Our intake team reviews your answers.
- 3. If it fits, an independent attorney or their team contacts you to explain your options.
- 4. You decide whether to move forward.
- Remember: the case review is free. Attorneys commonly work on contingency, and fee terms are set by the attorney.
Research shows semaglutide carries a 3.3× higher gastroparesis risk — and 19% of GLP-1 patients develop delayed gastric emptying.
Novo Nordisk did not adequately warn patients that Ozempic can cause stomach paralysis requiring hospitalization or feeding tube placement. The FDA added an ileus warning in September 2023 and updated the label in January 2025 — but thousands were harmed before these warnings were issued.
What Is the Ozempic Lawsuit About?
Ozempic (semaglutide) is a GLP-1 receptor agonist by Novo Nordisk used to treat Type 2 diabetes and, as Wegovy, for weight loss. Lawsuits allege Novo Nordisk failed to warn prescribers and patients that the drug can cause gastroparesis — stomach paralysis sometimes requiring hospitalization and feeding tube placement.
MDL 3094 is in the Eastern District of Pennsylvania under Judge Karen Spencer Marston. Over 3,191 cases were pending as of February 2026. No settlements have been reached.
Who Qualifies for the Ozempic Lawsuit?
You may qualify if you took Ozempic, Wegovy, Mounjaro, or another GLP-1 drug and developed a serious gastrointestinal condition, especially if you required hospitalization or surgery.
Did Ozempic or Wegovy cause your injury?
Get A Free Case ReviewHealth Conditions Alleged to Be Linked to Ozempic
- Gastroparesis — stomach paralysis, severe nausea and vomiting
- Intestinal obstruction — blockage requiring hospitalization or surgery
- Ileus — paralysis of the intestines
- Pulmonary aspiration — food entering the lungs due to delayed gastric emptying
- Acute kidney injury — from severe dehydration caused by vomiting
- Deep vein thrombosis (DVT)
Ozempic Lawsuit Timeline
- August 2023: First gastroparesis lawsuit filed (Bjorklund v. Novo Nordisk)
- September 2023: FDA added ileus warning to label
- February 2024: MDL 3094 formed with 55 initial cases
- January 2025:FDA updated label — Ozempic "not recommended in patients with severe gastroparesis"
- February 2026: 3,191 cases pending
- Late 2026: Bellwether trials anticipated
Last reviewed: · Lawsuit descriptions summarize allegations made in court filings, not proven facts.
